Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of atherosclerotic cardiovascular disease.
T h e ne w e ngl a nd jou r na l o f m e dicine A ngiopoietin-like proteins (ANGPTLs) have been established as important regulators of lipoprotein metabolism and have thus emerged as attractive targets for modulation of lipid levels and cardiovascular disease risk. Loss-of-function variants in ANGPTL4, a negative regulator of lipoprotein lipase (LPL) activity, are associated with decreased triglyceride levels, elevated high-density lipoprotein (HDL) cholesterol levels, and a reduced risk of coronary heart disease in humans. [1] [2] [3] [4] [5] In addition, loss-of-function variants in LPL have been shown to increase the risk of coronary artery disease, and gain-offunction variants have been shown to decrease the risk. [6] [7] [8] ANGPTL3 is an endogenous inhibitor of LPL that is related to ANGPTL4. Rare loss-of-function variants in ANGPTL3 have been shown to be associated with decreased triglyceride levels as well as decreased low-density lipoprotein (LDL) cholesterol and HDL cholesterol levels in family and general population studies of humans. 2, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Deletion of Angptl3 was also reported to reduce the development of atherosclerosis in Apoe-deficient mice. 20 In this study, we examined the relationship between ANGPTL3 loss-of-function variants and coronary artery disease in a large number of participants sampled from a large U.S. health care system, with follow-up studies in four population cohorts. We also evaluated the effects of pharmacologic antagonism of ANGPTL3 with a human monoclonal antibody on lipid metabolism and atherosclerosis in a mouse model of atherosclerosis and on lipid levels in human volunteers.
Me thods

Study Design and Oversight
The studies were designed and data analyses were performed by authors who were employees of the sponsor, Regeneron Pharmaceuticals, and of the Regeneron Genetics Center, with the involvement of two of the academic authors. Authors who are employees of the sponsor wrote the first draft of the manuscript, made the decision to submit the manuscript for publication, and vouch for the accuracy and completeness of the data and all analyses. The DiscovEHR study, other studies involving humans, and studies in animals were funded by Regeneron Pharmaceuticals; other funding sources are listed at the end of the article. The studies were approved by the Geisinger Health System institutional review board and each participating site. All participants in the studies involving humans gave informed written consent.
Human Genetics Cohorts
We conducted human genetics studies using DNA samples and data from five cohorts. These included the first 58,335 adult enrollees of European ancestry who provided consent to participate in the MyCode Community Health Initiative 21 of the Geisinger Health System (DiscovEHR study); a total of 107,888 persons from the Copenhagen City Heart Study, the Copenhagen General Population Study, and the Copenhagen Ischemic Heart Disease Study 22, 23 ; 7549 persons from the University of Pennsylvania Medicine BioBank (Penn); 5988 persons from the Duke Catheterization Genetics cohort (Duke) 24 ; and 9058 Taiwanese Chinese persons from the Taiwan Metabochip (TAICHI) consortium. 25, 26 Full study descriptions are provided in the Methods section and Tables S1 and S2 in the Supplementary Appendix (available with the full text of this article at NEJM.org).
Ascertainment of ANGPTL3 Loss-of-Function Variants and ANGPTL3 Concentration
In the DiscovEHR study, Penn, Duke, and TAICHI, ascertainment of ANGPTL3 loss-of-function variants was performed by whole-exome sequencing at the Regeneron Genetics Center, as described in the Supplementary Appendix. In the Copenhagen population studies, participants were directly genotyped for the p.Ser17Ter, p.Asn121fs, p.Asn147fs, and c.495+6T→C variants with the use of the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) and TaqMan-based assays or with the use of an allele-specific polymerasechain-reaction system (KASPer, LGC Genomics). Quantification of serum ANGPTL3 concentration was performed as described in the Supplementary Appendix.
Studies in Animals
APOE*3Leiden.CETP mice, an established model for hyperlipidemia with all features of mixed or familial dysbetalipoproteinemia and atherosclerosis, 27 were used for the evaluation of the effects of a fully human anti-ANGPTL3 monoclonal antibody, evinacumab (REGN1500), on athero-sclerosis. [28] [29] [30] (For antibody description and full experimental details, see the Supplementary Appendix.) A total of 50 female transgenic mice 31 on a Western-type diet were matched to one control group (20 mice) and one evinacumabtreated group (30 mice) on the basis of body weight and plasma levels of total cholesterol and triglycerides and were treated with evinacumab or isotype-matched antibody with irrelevant specificity (control antibody) by weekly subcutaneous injections at a dose of 25 mg per kilogram of body weight for 13 weeks. Mice in which a mouse antihuman antibody response developed were excluded (see the Supplementary Appendix). At 13 weeks, the mice were euthanized and atherosclerosis development in the aortic root was measured (15 mice per group), as described in the Supplementary Appendix. The study was conducted at TNO Metabolic Health Research (the Netherlands). All experiments involving animals were approved by the Institutional Animal Care and Use Committee of the Netherlands Organization for Applied Scientific Research.
Evinacumab Clinical Trial
A phase 1, first-in-human, randomized, placebocontrolled, double-blind, ascending single-dose clinical trial was performed to assess the safety, side-effect profile, and pharmacodynamics of REGN1500 (evinacumab) administered subcutaneously or intravenously to participants with varying degrees of dyslipidemia (see the Supplementary Appendix). The trial protocol is available at NEJM.org. The results for Group A of this trial are described in this report; Group A enrolled healthy men and women 18 to 65 years of age with a fasting triglyceride level of 150 to 450 mg per deciliter (1.7 to 5.1 mmol per liter) or an LDL cholesterol level of 100 mg per deciliter (2.6 mmol per liter) or greater.
Statistical Analysis
We used linear mixed models to test for associations of levels of total cholesterol, LDL cholesterol, log 10 HDL cholesterol, and log 10 triglycerides with genotype (for aggregated ANGPTL3 loss-of-function variants and the individual variants p.Ser17Ter, p.Asn121fs, p.Asn147fs, and c.495+6T→C) in the DiscovEHR study. Odds ratios for coronary artery disease were estimated in each study with the use of logistic regression or Firth's penalized likelihood method of logistic regression, 32 as described in the Supplementary Appendix. We then performed an inverse-variance-weighted fixed-effects meta-analysis and a Mantel-Haenszel fixed-effects meta-analysis of associations with coronary artery disease. For the study in mice, the significance of the differences between groups was determined with the use of the nonparametric Mann-Whitney U test for independent samples. For the clinical trial, an analysis of covariance (ANCOVA) model was used to compare the treatment effect in the evinacumab groups and the pooled placebo group; in the case of triglycerides, this was a rankbased ANCOVA. We used the following software programs for the statistical analyses of genetic data: GCTA software, version 1. 
R esult s
Loss-of-Function Variants in ANGPTL3
In 58,335 adult DiscovEHR study participants of European ancestry, we identified and confirmed (through Sanger sequencing) 13 distinct loss-offunction variants in ANGPTL3, including 4 different premature stop variants, 6 different open reading frame-shifting insertion-deletion variants, and 3 splice variants (Table S3 in the Supplementary Appendix). The demographic and clinical characteristics of the study population according to variant status are shown in Table S4 in the Supplementary Appendix.
The most frequently observed ANGPTL3 loss-offunction variants were p.Ser17Ter (in 21 persons), which has been previously described to segregate with combined hypolipidemia in family studies 14, 16 ; p.Asn121fs (in 91 persons), which has been previously observed in a population sample and associated with reduced LDL cholesterol levels 16 ; and a novel rare frame-shifting insertion-deletion variant at position 147 (p.Asn147fs, in 52 persons). A splice region variant, c.495+6T→C, was identified in 57 persons and was found to be associated with a decreased concentration of ANGPTL3 protein, similar to the other loss-offunction variants; thus, it was included in all T h e ne w e ngl a nd jou r na l o f m e dicine loss-of-function analyses. A total of 246 persons were heterozygous for loss-of-function variants, corresponding to a total carrier frequency of 1 in 237 DiscovEHR study participants of European ancestry. As expected, given the allele frequencies, we did not find homozygotes or compound heterozygotes.
The median concentration of ANGPTL3 protein among 125 carriers of loss-of-function variants was 50 ng per milliliter (interquartile range, 38 to 62) and among 53 matched noncarriers was 99 ng per milliliter (interquartile range, 80 to 127) (P = 9.4×10 −16 by Mann-Whitney U test). Protein abundance according to allele is shown in Figure 1 .
Loss-of-Function Variants in ANGPTL3, Lipid Levels, and Coronary Artery Disease
We performed tests of association between lossof-function variants (both individually and aggregated over ANGPTL3) and median serum lipid measures in up to 45,226 persons in the DiscovEHR study who had documented lipid levels in the electronic health record (Table 1 and Fig. 1, and  Tables S5 and S6 in the Supplementary Appendix). Overall, carriers of loss-of-function variants had 27% lower triglyceride levels than noncarriers (P = 2.5×10 −21 ), 9% lower LDL cholesterol levels (P = 2.8×10 −5 ), and 4% lower HDL cholesterol levels (P = 0.02), after adjustment for covariates.
We then tested for association between ANGPTL3 loss-of-function variants and coronary artery disease. Overall, 43 of the 13,102 persons with coronary artery disease (cumulative carrier frequency, 0.33%) and 183 of the 40,430 controls (cumulative carrier frequency, 0.45%) carried a loss-offunction variant. After adjustment for age, sex, and the principal components of ancestry, the presence of an ANGPTL3 loss-of-function variant was associated with a 41% lower odds of coronary artery disease (adjusted odds ratio for any loss-of-function variant, 0.59; 95% confidence interval [CI], 0.41 to 0.85; P = 0.004); these variants were also associated with numerically, but not significantly, lower odds of myocardial infarction (carrier frequencies, 0.36% among persons with myocardial infarction and 0.45% among controls; odds ratio, 0.66; 95% CI, 0.39 to 1.06; P = 0.09). Individually, each of the four most abundant loss-of-function variants (p.Ser17Ter, p.Asn121fs, p.Asn147fs, and c.495+6T→C) was less frequent among case patients with coronary artery disease than among controls (Table S7 in the Supplementary Appendix). In a subgroup of the sequenced cohort in which only 1 person in every first-degree and second-degree relationship was retained (9261 case patients and 29,778 controls), ANGPTL3 loss-of-function variants were associated with lower odds of coronary artery disease (carrier frequencies, 0.31% among persons with coronary artery disease and 0.44% among controls; odds ratio, 0.61; 95% CI, 0.39 to 0.94; P = 0.03).
We sought additional evidence of an association between ANGPTL3 loss-of-function variants and coronary artery disease in 23,317 case patients with coronary artery disease and 107,166 controls from four independent population studies (Copenhagen General Population Study, Duke, Penn, and TAICHI) ( Table S2 in the Supplementary Appendix). In these studies, we observed a numerically, but not significantly, lower odds of coronary artery disease among carriers of these variants (odds ratio, 0.63; 95% CI, 0.39 to 1.02; P = 0.06). An inverse-variance-weighted fixedeffects meta-analysis of the association of ANGPTL3 loss-of-function variants with coronary artery disease in the DiscovEHR study and these other population studies yielded an overall odds ratio of 0.61 (95% CI, 0.45 to 0.81; P<0.001) (Fig. 2) . A Mantel-Haenszel fixed-effects meta-analysis, a method that is robust to low counts, yielded similar results (odds ratio, 0.69; 95% CI, 0.53 to 0.89; P = 0.006) without evidence of significant heterogeneity (Q = 3.94, I 2 = 0%, P = 0.40 for heterogeneity).
Inhibition of Angptl3 in a Mouse Model of Atherosclerosis
We evaluated the effect of an anti-ANGPTL3 monoclonal antibody candidate therapeutic 30 on atherosclerosis in APOE*3Leiden.CETP mice. Evinacumab administration was associated with a significantly lower average total cholesterol level than the control antibody (difference, −52%; P<0.001) and a significantly lower triglyceride level (difference, −84%; P<0.001) by a reduction of the apoB-containing atherogenic lipoproteins (Fig. 3A through 3D) . Evinacumab was associated with a significantly greater decrease in atherosclerotic lesion size than the control antibody (difference, −39%; P<0.001) (Fig. 3E and 3F ). Treatment with evinacumab was associated with a significantly greater decrease in necrotic content in severe type IV and V lesions than the control antibody (difference, −45%; P = 0.001), but there were no significant differences in macro- T h e ne w e ngl a nd jou r na l o f m e dicine phage content, collagen content, or smooth muscle cell area ( Fig. 3G and 3H ).
ANGPTL3 Inhibition with Evinacumab in Healthy Human Volunteers
We evaluated the effects of evinacumab on lipid levels in healthy human volunteers with mildly to moderately elevated levels of triglycerides (150 to 450 mg per deciliter) or LDL cholesterol (≥100 mg per deciliter). A total of 83 participants at three U.S. sites entered a single-ascending-dose trial involving randomization to evinacumab (administered subcutaneously or intravenously) or placebo in a 3:1 ratio (see the Methods section and Fig. S1 in the Supplementary Appendix). The baseline characteristics of the participants are presented in Tables S8 and S9 in the Supplementary Appendix. The most frequent adverse event among the evinacumab-treated patients was headache (seven patients; 11%). Transient, single elevations of the alanine aminotransferase level to more than 3 times the upper limit of the normal range were observed in two evinacumab-treated patients (3%), both of whom had an alanine aminotransferase level above the upper limit of the normal range at baseline or screening. There were no discontinuations due to adverse safety events (Tables S10 and S11 in the Supplementary Appendix).
The time course of triglyceride, LDL cholesterol, and HDL cholesterol responses to escalating doses of evinacumab or placebo are shown in Figure 4 , and in Figures S2 and S3 in the Supplementary Appendix. The magnitude and duration of lipid reductions (placebo-corrected) were dose-proportional. The maximal changes in lipid levels found among patients who received a dose of 20 mg per kilogram intravenously were as follows: triglycerides, −76.0% (day 4); directly measured LDL cholesterol, −23.2% (day 15); and HDL cholesterol, −18.4% (day 15). A full summary of treatment effects is presented in Tables S12 through S17 in the Supplementary Appendix.
Discussion
We performed whole-exome sequencing in 58,335 adult participants of European ancestry in the DiscovEHR study, which links genetic data to electronic health records in a large integrated health system, along with targeted genotyping of ANGPTL3 loss-of-function variants and wholeexome sequencing in four other population cohorts comprising 130,483 persons. Using these methods, we identified more than 400 persons who harbor heterozygous loss-of-function variants in ANGPTL3. Persons heterozygous for ANGPTL3 loss-of-function variants had approximately 50% lower ANGPTL3 levels than noncarriers and 
Associations between ANGPTL3 Predicted Loss-of-Function Variants and Lipid Levels in DiscovEHR Study
Participants.* 39% lower odds of coronary artery disease. These results mirror the reduction in plasma lipid levels and atherosclerosis progression that we observed in dyslipidemic mice treated with evinacumab, a human monoclonal antibody inhibitor of ANGPTL3. The pattern and magnitude of reduction in atherosclerotic lesion area that was observed in this mouse model treated with evinacumab was similar to that reported previously in the same mouse model treated with atorvastatin. 34 Our results provide evidence that the combined hypolipidemia profile associated with genetic or therapeutic antagonism of ANGPTL3, which includes a reduction in levels of HDL cholesterol in addition to LDL cholesterol and triglycerides, is antiatherogenic.
ANGPTL3 inhibition affects lipid levels in several ways. Triglyceride reduction is mediated at least in part through disinhibition of LPL and subsequent hydrolysis of triglyceride-rich lipoproteins. HDL cholesterol reduction is mediated by disinhibition of endothelial lipase. 13, 30 The reduction in LDL cholesterol levels with ANGPTL3 antagonism occurs through a mechanism that has yet to be elucidated. However, studies in Ldlr-deficient mice indicate that ANGPTL3 modulates LDL cholesterol in a manner that is independent of the LDL receptor and other known mechanisms responsible for clearance of plasma LDL cholesterol. 35 These findings suggest that therapeutic antagonism of ANGPTL3 should be efficacious in lowering LDL cholesterol levels in persons with a complete deficiency in LDL receptor-mediated LDL cholesterol uptake, such as persons affected by homozygous familial hypercholesterolemia. Additional human genetics support for targeting this pathway is provided by evidence of similar reductions in coronary artery disease risk that are associated with inactivating variants in ANGPTL4, 5 a related inhibitor of LPL, and genetic variants in LPL that increase LPL activity. 6, 7 Evidence to date does not suggest that genetic perturbation of LIPG, the gene encoding endothelial lipase, is associated with coronary artery disease, despite robust associations with HDL cholesterol levels. 36 We also report here clinical pharmacology results from a trial involving therapeutic antagonism of ANGPTL3 in human volunteers treated with evinacumab. We found dose-dependent reductions in levels of triglycerides and LDL cholesterol that appear to recapitulate the lipid phenotype of patients with ANGPTL3 loss-of-function variants. In addition to the ANGPTL3 loss-of- The association between the ANGPTL3 loss-of-function variants and coronary artery disease (CAD) was tested in each study with the use of logistic regression or Firth's penalized likelihood logistic regression. Combined effects were determined by inverse-varianceweighted fixed-effects meta-analysis. For each study, the square indicates the odds ratio and the line indicates the 95% confidence interval. The square size is proportional to the precision of the estimate. For the combined estimate, the center of the diamond indicates the odds ratio for the meta-analysis, with the left and right corners of the diamond indicating the boundaries of the 95% confidence interval. ANGPTL3 loss-of-function variants were ascertained by means of targeted genotyping in the Copenhagen General Population Studies (CGPS) and by means of exome sequencing in the other studies. Duke denotes the Duke Catheterization Genetics cohort, GHS Geisinger Health System (DiscovEHR study), Penn the University of Pennsylvania Medicine BioBank, and TAICHI the Taiwan Metabochip consortium. function heterozygotes in this study, more than 200 heterozygous carriers and more than 20 homozygotes of ANGPTL3 loss-of-function variants have been reported by others with no apparent negative effects on cardiometabolic traits and diseases evaluated in these participants. 14, 37, 38 A recent study has shown an association between ANGPTL3 deficiency and protection from coronary artery disease, 38 a finding consistent with those of our study. In aggregate, these data support further investigation of inhibition of ANGPTL3 as a therapeutic target for lipid modification and possible reduction in the risk of atherosclerotic cardiovascular disease in humans.
Our study has limitations. Our human genetics studies largely involved persons of European ancestry; it is not known whether our observations will generalize to persons of other ancestries. We did not directly evaluate coronary atherosclerosis progression; instead, we evaluated aortic Figure 3 (facing page) . Effect of Inhibition of Angptl3 with a Monoclonal Antibody in APOE*3Leiden.CETP Mice.
Evinacumab reduced plasma levels of total cholesterol (Panel A) and triglycerides (Panel B) in APOE*3Leiden.CETP mice throughout the 13 weeks of the study. Plasma lipoproteins were separated on fast protein liquid chromatography at the end of the study and assessed for total cholesterol (Panel C) and triglycerides (Panel D). Representative images of atherosclerotic lesions (hematoxylin-phloxine-saffron stain) in a cross section of the aortic root area that was used for area quantification are shown (Panel E); the total atherosclerotic lesion area per cross section was evaluated at the end of the study (Panel F). Macrophage and necrotic content (indicators of lesion inflammation) (Panel G) and smooth muscle cells (SMC) and collagen content (indicators of lesion stability) (Panel H) were determined in the severe (type IV and V) lesions and normalized to lesion size. All values in Panels A, B, and F through H are means ±SE. For Panels A through D, 14 mice were given the control antibody and 22 were given evinacumab. The analysis conducted in Panels E through H involved 14 mice given the control antibody and 15 given evinacumab. VLDL denotes very-low-density lipoprotein.
T h e ne w e ngl a nd jou r na l o f m e dicine atherosclerosis progression in a mouse model. The sample size of our clinical trial was limited, and the trial included healthy human volunteers, not those selected for severe dyslipidemias or established cardiovascular disease. Finally, the associations with lipid levels and coronary artery disease in our human genetics studies were observed in heterozygotes who had a reduction in ANGTPL3 levels of approximately 50%, which had probably been present since birth. Whether such observations accurately reflect the phenotypic effects of a more complete blockade of ANGPTL3 later in life, with the use of a monoclonal antibody, is not clear.
In conclusion, we observed that loss-of-function variants in ANGPTL3 were associated with a reduced risk of coronary artery disease, mirroring the antiatherogenic effects of inhibition of Angptl3 by monoclonal antibody in mice. In human volunteers, monoclonal antibody inhibition of ANGPTL3 was associated with dose-dependent reductions in LDL cholesterol and triglyceride levels. Taiwan (TCVGH-1020101C, TCVGH-1020102D,  TCVGH-1023102B, TCVGH-1023107D, TCVGH-1030101C, TCVGH-1030105D, TCVGH-1033503C, TCVGH-1033102B, TCVGH-1033108D , TCVGH-1040101C, TCVGH-1040102D, TCVGH-1043504C, and TCVGH-1043104B); it was also supported in part by the National Center for Advancing Translational Sciences (CTSI grant UL1TR001881).
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